Metformin inhibits the growth of human pancreatic cancer xenografts

Pancreas

Volumn 42, Issue 5, 2013, Pages 781-785

  Kisfalvi, Krisztina ^a   Moro, Aune ^a   Sinnett Smith, James ^a,b   Eibl, Guido ^a,b   Rozengurt, Enrique ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ERK; MiaPaCa 2 cells; MTORC1; Orthotopic tumor xenografts; PANC 1 cells; Pancreatic ductal adenocarcinoma

Indexed keywords

METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAPERITONEAL; MALE; METFORMIN; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880047529     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31827aec40     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O., et al Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-236.
2. Chari ST, Leibson CL, Rabe K.G., et al Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504-511.
3. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-2083.
4. Michaud DS, Wolpin B, Giovannucci E., et al Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007;16:2101-2109.
5. Stolzenberg-Solomon R.Z., Graubard BI, Chari S, et al Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294:2872-2878.
6. Jee SH, Ohrr H, Sull J.W., et al Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194-202.
7. Giovannucci E, Harlan DM, Archer M.C., et al Diabetes and cancer. Diabetes Care. 2010;33:1674-1685.
8. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010;101:1073.
9. Arslan AA, Helzlsouer KJ, Kooperberg C, et al Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010;170:791-802.
10. Giovannucci E, Harlan DM, Archer M.C., et al Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207-221.
11. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337-350.
12. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-591.
13. Calle EE, Thun MJ Obesity and cancer. Oncogene. 2004;23:6365-6378.
14. Muoio DM, Newgard CB Obesity-related derangements in metabolic regulation. Annu Rev Biochem. 2006;75:367-401.
15. Tam CS, Viardot A, Clement K., et al Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes. 2010;59:2164-2170.
16. Ballian N, Brunicardi FC Islet vasculature as a regulator of endocrine pancreas function. World J Surg. 2007;31:705-714.
17. Bertelli E, Regoli M, Orazioli D., et al Association between islets of Langerhans and pancreatic ductal system in adult rat. Where endocrine and exocrine meet together? Diabetologia. 2001;44:575-584.
18. Kisfalvi K, Rey O, Young S.H., et al Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology. 2007;148:3246-3257.
19. Taniguchi CM, Emanuelli B, Kahn CR Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85-96.
20. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/ insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010;16:2505-2511.
21. Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108:1105-1107.
22. Kahn BB, Alquier T, Carling D., et al AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
23. Evans JM, Donnelly LA, Emslie-Smith AM, et al Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
24. Bowker SL, Majumdar SR, Veugelers P, et al Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-258.
25. Libby G, Donnelly LA, Donnan P.T., et al New users of metformin are at low risk of incident cancer. Diabetes Care. 2009;32:1620-1625.
26. Chong CR, Chabner BA Mysterious metformin. Oncologist. 2009;14:1178-1181.
27. Ben Sahra I., Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9:1092-1099.
28. Landman GWD, Kleefstra N, van Hateren KJJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care. 2010;33:322-326.
29. DeCensi A, Puntoni M, Goodwin P., et al Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3:1451-1461.
30. Li D, Yeung S-CJ, Hassan MM, et al Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482-488.
31. Currie CJ, Poole CD, Gale EA The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777.
32. Lee MS, Hsu CC, Wahlqvist M.L., et al Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
33. Kisfalvi K, Eibl G, Sinnett-Smith J, et al Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009;69:6539-6545.
34. Eibl G, Reber HA A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas. 2005;31:258-262.
35. Guha S, Eibl G, Kisfalvi K., et al Broad-spectrum G protein-coupled receptor antagonist, [D-Arg 1, D-Trp 5, 7, 9, Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005;65:2738-2745.
36. Bergheim I, Guo L, Davis M.A., et al Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastro e ntero log y. 2006;130:2099-2112.
37. Buzzai M, Jones RG, Amaravadi R.K., et al Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745-6752.
38. Ma TC, Buescher JL, Oatis B, et al Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett. 2007;411:98-103.
39. Memmott RM, Mercado JR, Maier C.R., et al Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res. 2010;3:1066-1076.
40. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature. 2007;448:645-646.